Susha Cheriyedath

Feature Writer

B.Sc Chemistry, M.Sc. Biochemistry

Susha is a scientific communication professional holding a Master's degree in Biochemistry, with expertise in Microbiology, Physiology, Biotechnology, and Nutrition. After a two-year tenure as a lecturer from 2000 to 2002, where she mentored undergraduates studying Biochemistry, she transitioned into editorial roles within scientific publishing. She has accumulated nearly two decades of experience in medical communication, assuming diverse roles in research, writing, editing, and editorial management.

Passionate about health and nutrition, Susha is interested in various diet types, such as veganism, and their impact on the body and metabolism. She remains dedicated to staying current with the latest developments in the medical and health science fields. In her leisure time, she engages in gardening, cooking/baking, and sketching/painting. When not immersed in work, she can often be found tending to her garden (weather permitting) or engrossed in her sketching and painting projects.

See less

Articles from Susha

Impact of maternal SARS-CoV-2 infection on neonatal immunology

Although extensive studies have been carried out on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and evidence exists that pregnant women are at elevated risk of severe COVID-19, the impact of maternal infection on the fetus is not clear. The majority of pregnant women infected with SARS-CoV-2 are asymptomatic or experience mild symptoms.

7 Jun 2021

Post-COVID-19 assessment shows long-lasting consequences for many non-hospitalized individuals

Complications following COVID-19 infection require quick identification and management to help plan policy and health system responses. Researchers in the UK recently described the 12-month experience of the first dedicated post-COVID clinical service in the UK to include both hospitalized and non-hospitalized COVID-19 patients. This study has been released on the medRxiv* the preprint server.

4 Jun 2021

Could a green tea compound combat SARS-CoV-2?

Researchers recently published an article that reviewed the mechanisms by which EGCG could inhibit SARS-CoV-2 infection and the various syndromes caused by COVID-19.

3 Jun 2021

Heterologous AstraZeneca and Pfizer vaccines induce strong immune response and T cell reactivity against multiple SARS-CoV-2 variants

Researchers from Germany recently analyzed a cohort of 26 individuals in the age range of 25 to 46 (median 30.5) years who had received a ChAdOx1 nCoV-19 prime vaccine followed by a BNT162b2 boost vaccine after a 56-day interval due to changing vaccine recommendations in Germany. There were 16 females and 10 males in the cohort, and they were assessed for immune responses, reactogenicity, and T cell reactivity. This study is published on the medRxiv* preprint server.

3 Jun 2021

Study explores COVID-19 vaccine beliefs and behaviors among college students

A recent study conducted by researchers at Pennsylvania State University in the US explored the beliefs and attitudes of students about vaccination in general and the COVID-19 vaccines in particular.

3 Jun 2021

Is COVID-19 vaccination in California equitable yet?

Researchers from the University of California, Davis recently conducted a short investigation to examine current vaccine equity and forecasts of vaccine coverage in California by June 15, 2020, in various scenarios.

1 Jun 2021

Study confirms poor immunogenicity in hemodialysis patients receiving single dose BNT162b2 vaccine

Researchers from Ontario, Canada, recently conducted a prospective observational study to determine the SARS-CoV-2 antibody response in chronic hemodialysis patients following one vs. two doses of the BNT162b2 COVID-19 vaccine. The results were compared to health care worker controls and convalescent serum.

1 Jun 2021

Compelling evidence of SARS-CoV-2 exposure and neutralizing antibodies in domestic cats in Peru

Although Peru is one of the countries most affected by the pandemic, no studies had been conducted to investigate SARS-CoV-2 seroprevalence among domestic cats. Recently, researchers from Peru demonstrated the presence of neutralizing antibodies for the receptor binding-domain (RBD) of the SARS-CoV-2 spike protein in cats in Lima, Peru. The owners of the cats in the study had confirmed SARS-CoV-2 infection.

1 Jun 2021

Antibody cocktail effectively inhibits SARS-CoV-2 in the rhesus macaque model

Researchers from the US tested the prophylactic potential of a combination of 2 mAbs administered 3 or 75 days before respiratory challenge in rhesus macaques. They used the rhesus macaque model to test the added benefit of combinatory parenteral administration of 2 high-affinity anti-SARS-CoV-2 mAbs - C144-LS and C135-LS. These mAbs were developed to neutralize the virus and tweaked to improve their pharmacokinetics.

1 Jun 2021

ALG-097111 potently inhibits SARS-CoV-2 replication in Syrian Hamster model in vivo

A team of researchers from the US and Belgium applied a structure-based approach with early monitoring of cathepsin L inhibition along with SARS-CoV-2 3CLpro inhibition. They identified a potent and selective SARS-CoV-2 3CLpro inhibitor, ALG-097111, which has proven activity against SARS-CoV-2 in SARS-CoV-2 hamster models in vivo. This study is published in the journal, Biochemical and Biophysical Research Communications.

1 Jun 2021